Coya Therapeutics to Detail ALSTARS Trial Design at ENCALS 2026 — Coya Therapeutics, Inc.

Event summary

Coya Therapeutics will present the design of its ALSTARS Phase 2 trial at the ENCALS 2026 Meeting in Madrid on June 24, 2026.
The trial, led by Tyrell Simkins, D.O., Ph.D., aims to evaluate the efficacy and safety of COYA 302 in treating ALS.
COYA 302 is a proprietary biologic combination therapy targeting neuroinflammation through Treg enhancement.
The ALSTARS trial is a randomized, multi-center, double-blind, placebo-controlled study (ClinicalTrials.gov Identifier: NCT07161999).

The big picture

Coya Therapeutics' presentation at ENCALS 2026 underscores the growing focus on immunomodulatory approaches to treat neurodegenerative diseases like ALS. The company's proprietary biologic combination therapy, COYA 302, aims to enhance Treg function, addressing a critical unmet need in neuroinflammation management. Success in the ALSTARS trial could position Coya as a key player in the biotech space, particularly if it can differentiate its approach from existing treatments.

What we're watching

Trial Execution: The pace at which Coya Therapeutics can enroll and complete the ALSTARS trial will determine the timeline for potential regulatory approvals.
Therapeutic Efficacy: Whether COYA 302 can demonstrate significant efficacy in modulating neuroinflammation and slowing ALS progression.
Market Positioning: How Coya Therapeutics positions itself against competitors developing similar immunomodulatory therapies for neurodegenerative diseases.